314 related articles for article (PubMed ID: 37446214)
1. The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy.
Anderson R; Feldman C
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446214
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.
Anderson R; Nel JG; Feldman C
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641429
[TBL] [Abstract][Full Text] [Related]
3. Platelets and Their Role in the Pathogenesis of Cardiovascular Events in Patients With Community-Acquired Pneumonia.
Feldman C; Anderson R
Front Immunol; 2020; 11():577303. PubMed ID: 33042161
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
Domon H; Maekawa T; Yonezawa D; Nagai K; Oda M; Yanagihara K; Terao Y
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181369
[No Abstract] [Full Text] [Related]
5. Clarithromycin Inhibits Pneumolysin Production via Downregulation of
Domon H; Isono T; Hiyoshi T; Tamura H; Sasagawa K; Maekawa T; Hirayama S; Yanagihara K; Terao Y
Microbiol Spectr; 2021 Oct; 9(2):e0031821. PubMed ID: 34468195
[TBL] [Abstract][Full Text] [Related]
6. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease.
Cockeran R; Anderson R; Feldman C
Arch Immunol Ther Exp (Warsz); 2005; 53(3):189-98. PubMed ID: 15995579
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community-acquired pneumonia.
Feldman C; Normark S; Henriques-Normark B; Anderson R
J Intern Med; 2019 Jun; 285(6):635-652. PubMed ID: 30584680
[TBL] [Abstract][Full Text] [Related]
8. The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.
Feldman C; Anderson R
Semin Respir Crit Care Med; 2016 Dec; 37(6):806-818. PubMed ID: 27960205
[No Abstract] [Full Text] [Related]
9. Drug treatment of pneumococcal pneumonia in the elderly.
Neralla S; Meyer KC
Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950
[TBL] [Abstract][Full Text] [Related]
10. Pneumolysin as a potential therapeutic target in severe pneumococcal disease.
Anderson R; Feldman C
J Infect; 2017 Jun; 74(6):527-544. PubMed ID: 28322888
[TBL] [Abstract][Full Text] [Related]
11. Hidden epidemic of macrolide-resistant pneumococci.
Klugman KP; Lonks JR
Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
[TBL] [Abstract][Full Text] [Related]
12. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
[TBL] [Abstract][Full Text] [Related]
13. [Thousand faces of Streptococcus pneumonia (pneumococcus) infections].
Szabó BG; Lénárt KS; Kádár B; Gombos A; Dezsényi B; Szanka J; Bobek I; Prinz G
Orv Hetil; 2015 Nov; 156(44):1769-77. PubMed ID: 26498896
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
[TBL] [Abstract][Full Text] [Related]
15. Bacteraemic pneumococcal pneumonia: current therapeutic options.
Feldman C; Anderson R
Drugs; 2011 Jan; 71(2):131-53. PubMed ID: 21275443
[TBL] [Abstract][Full Text] [Related]
16. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased?
Vallès X; Marcos A; Pinart M; Piñer R; Marco F; Mensa JM; Torres A
Chest; 2006 Sep; 130(3):800-6. PubMed ID: 16963678
[TBL] [Abstract][Full Text] [Related]
17. The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.
Feldman C; Anderson R
Semin Respir Crit Care Med; 2020 Aug; 41(4):455-469. PubMed ID: 32629486
[TBL] [Abstract][Full Text] [Related]
18. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
[TBL] [Abstract][Full Text] [Related]
19. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
Yayan J
Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.
Mongardon N; Max A; Bouglé A; Pène F; Lemiale V; Charpentier J; Cariou A; Chiche JD; Bedos JP; Mira JP
Crit Care; 2012 Aug; 16(4):R155. PubMed ID: 22894879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
